Search result for 'eris lifesciences'

Eris Lifesciences reported a 20% decline in Q2 profit to Rs 97 crore, but revenue increased to Rs 741 crore. The company is on track to achieve revenue guidance of Rs 2,600 crore in domestic...

ChrysCapital has exited Eris Lifesciences by selling its 7.27% stake for Rs 1,187 crore via an open market transaction. Infinity Partners acquired the shares.

Biocon's Q1 profit jumps six-fold to Rs 660 crore, driven by a one-time gain from the Biocon Biologics and Eris Lifesciences collaboration. Revenue also grew slightly.

Eris Lifesciences reports a 4.5% decline in consolidated profit after tax to Rs 89 crore for Q1 FY25, while revenue rose to Rs 720 crore. The company expects significant growth in its Biocon business.

Rakesh Shah, a shareholder of Eris Lifesciences, has divested a 1.5% stake in the company for Rs 200 crore through an open market transaction. The shares were offloaded at an average price of Rs...

Eris Lifesciences has acquired a 51% stake in Swiss Parenterals, a leading sterile injectable manufacturer, for Rs 637.5 crore. The acquisition strengthens Eris's India footprint and complements...

Biocon Biologics has sold its dermatology and nephrology branded formulations business units in India to Eris Lifesciences for Rs 366 crore. The deal is expected to close by the end of November 2023.